Galapagos NV

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

17 Sep 2021 06:15:00 By Nasdaq GlobeNewswire

Galapagos announces planned retirement of CEO

30 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos reports H1 financial results with refocused pipeline and operational progress

05 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

14 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

14 Jul 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

10 Jul 2021 04:10:00 By Nasdaq GlobeNewswire

Galapagos announces departure of CSO Piet Wigerinck later this year

22 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

07 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

SELECTION study on filgotinib in ulcerative colitis published in The Lancet

04 Jun 2021 00:01:00 By Nasdaq GlobeNewswire

Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress

27 May 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

18 May 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos refocuses pipeline and rightsizes operations  

06 May 2021 15:01:00 By Nasdaq GlobeNewswire

Transparency notification received from The Capital Group

04 May 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos creates new subscription right plans

30 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

22 Apr 2021 23:01:00 By Nasdaq GlobeNewswire

Extension of lock-up period in Gilead-Galapagos collaboration agreement

08 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

Publication of the annual report and invitation to the ordinary shareholders’ meeting

25 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos appoints Bart Filius as President and Chief Operating Officer

24 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Galapagos increases share capital through subscription right exercises

19 Mar 2021 16:01:00 By Nasdaq GlobeNewswire

GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES

04 Mar 2021 00:49:18 By Nasdaq GlobeNewswire